Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC …
Oct 23, 2024 · New preclinical data on PRMT5-MTA inhibitor program will also be presented. NEW YORK, NY, USA I October 23, 2024 I Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in ...
Vertex Announces US FDA Approval of ALYFTREK™,a Once-Daily …
Dec 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
NiKang Therapeutics® Presents Discovery of NKT3964, a First-in …
Oct 25, 2024 · About NKT3964. NKT3964 is a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader, causing prolonged CDK2 pathway inhibition without cyclin E accumulation.
DATROWAY® Approved in Japan as the First TROP-2 Directed …
Dec 27, 2024 · First global approval based on TROPION-Breast01 where DATROWAY significantly reduced the risk of disease progression or death by 37% versus chemotherapy
Evommune Presents Positive Clinical Results of its MRGPRX2 …
Dec 4, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
FDA approves Zepbound® (tirzepatide) as the first and only …
Dec 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Pierre Fabre Laboratories and Scorpion Therapeutics Announce …
Oct 9, 2024 · [1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, October 2016 [2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., August 2015 [3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, November 2015 [4] Choudhury NJ et al 2022, J Thoracic Onc 18, 463 [5] Olsen S et al 2022, Current Onc 29, 4811
Sumitomo Pharma America Announces U.S. FDA Approval of …
Dec 23, 2024 · – GEMTESA ® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – . MARLBOROUGH, MA, USA I December 23, 2024 I Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved GEMTESA ® (vibegron), a beta-3 (β 3) adrenergic receptor agonist, dosed once ...
Hope Medicine Inc. Announces Positive Results from a Global …
Oct 24, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Marea Therapeutics Provides Update on Corporate Progress …
Jan 10, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …